Do analysts prefer PAVM or MBAI?

PAVmed presently has a consensus price target of $56.00, indicating a potential upside of 1,303.51%. Given PAVmed's stronger consensus rating and higher probable upside, equities analysts clearly believe PAVmed is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PAVmed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PAVM or MBAI more profitable?

Check-Cap has a net margin of 0.00% compared to PAVmed's net margin of -10,794.64%. Check-Cap's return on equity of 0.00% beat PAVmed's return on equity. Company Net Margins Return on Equity Return on Assets PAVmed -10,794.64% -126.43% -25.49% Check-Cap N/A N/A N/A

Does the media refer more to PAVM or MBAI?

In the previous week, PAVmed and PAVmed both had 1 articles in the media. PAVmed's average media sentiment score of 0.00 equaled Check-Cap'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PAVmed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Check-Cap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate IINN or MBAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inspira Technologies OXY B.H.N. 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, IINN or MBAI?

Check-Cap has lower revenue, but higher earnings than Inspira Technologies OXY B.H.N.. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inspira Technologies OXY B.H.N. $289K 97.02 -$13.22M N/A N/A Check-Cap N/A N/A $4.14M -$14.07 N/A

Is IINN or MBAI more profitable?

Company Net Margins Return on Equity Return on Assets Inspira Technologies OXY B.H.N. N/A N/A N/A Check-Cap N/A N/A N/A

Do analysts recommend MBAI or QTEX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Inspira Technologies OXY B.H.N. 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, MBAI or QTEX?

Check-Cap has higher earnings, but lower revenue than Inspira Technologies OXY B.H.N.. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Check-Cap N/A N/A $4.14M -$14.07 N/A Inspira Technologies OXY B.H.N. $290K 95.45 -$13.22M N/A N/A

Is MBAI or QTEX more profitable?

Company Net Margins Return on Equity Return on Assets Check-Cap N/A N/A N/A Inspira Technologies OXY B.H.N. N/A N/A N/A

Does the media prefer MBAI or QTEX?

In the previous week, Check-Cap and Check-Cap both had 1 articles in the media. Check-Cap's average media sentiment score of 0.00 equaled Inspira Technologies OXY B.H.N.'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Check-Cap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inspira Technologies OXY B.H.N. 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ARAY or MBAI?

Accuray presently has a consensus price target of $2.00, indicating a potential upside of 786.92%. Given Accuray's stronger consensus rating and higher possible upside, research analysts plainly believe Accuray is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Accuray 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ARAY or MBAI more profitable?

Check-Cap has a net margin of 0.00% compared to Accuray's net margin of -12.24%. Check-Cap's return on equity of 0.00% beat Accuray's return on equity. Company Net Margins Return on Equity Return on Assets Accuray -12.24% -97.85% -10.82% Check-Cap N/A N/A N/A

Does the media refer more to ARAY or MBAI?

In the previous week, Accuray and Accuray both had 1 articles in the media. Accuray's average media sentiment score of 0.00 equaled Check-Cap'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accuray 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Check-Cap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PETV or MBAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PETV or MBAI more profitable?

Check-Cap has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. Check-Cap's return on equity of 0.00% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets PetVivo -902.82% -4,813.07% -281.78% Check-Cap N/A N/A N/A

Does the media favor PETV or MBAI?

In the previous week, PetVivo had 2 more articles in the media than Check-Cap. MarketBeat recorded 3 mentions for PetVivo and 1 mentions for Check-Cap. PetVivo's average media sentiment score of 0.00 equaled Check-Cap'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Check-Cap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Check-Cap (MBAI) Competitors

$5.47 -0.91 (-14.26%)

Closing price 09/23/2026 03:59 PM Eastern

Extended Trading

$5.23 -0.24 (-4.33%)

As of 04:01 AM Eastern

Compare

MBAI vs. PAVM, IINN, QTEX, ARAY, and PETV

Should you buy Check-Cap stock or one of its competitors? Check-Cap's main competitors and comparable companies include PAVmed (PAVM), Inspira Technologies OXY B.H.N. (IINN), Inspira Technologies OXY B.H.N. (QTEX), Accuray (ARAY), and PetVivo (PETV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Check-Cap compare to PAVmed?

PAVmed (NASDAQ:PAVM) and Check-Cap (NASDAQ:MBAI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

In the previous week, PAVmed and PAVmed both had 1 articles in the media. PAVmed's average media sentiment score of 0.00 equaled Check-Cap'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PAVmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PAVmed presently has a consensus price target of $56.00, indicating a potential upside of 1,303.51%. Given PAVmed's stronger consensus rating and higher probable upside, equities analysts clearly believe PAVmed is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Check-Cap has lower revenue, but higher earnings than PAVmed. Check-Cap is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	456.00	$400K	-$16.05	N/A
Check-Cap	N/A	N/A	$4.14M	-$14.07	N/A

PAVmed has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Check-Cap has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

19.9% of PAVmed shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 13.4% of PAVmed shares are held by company insiders. Comparatively, 0.5% of Check-Cap shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Check-Cap has a net margin of 0.00% compared to PAVmed's net margin of -10,794.64%. Check-Cap's return on equity of 0.00% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-10,794.64%	-126.43%	-25.49%
Check-Cap	N/A	N/A	N/A

Summary

PAVmed beats Check-Cap on 7 of the 13 factors compared between the two stocks.

How does Check-Cap compare to Inspira Technologies OXY B.H.N.?

Inspira Technologies OXY B.H.N. (NASDAQ:IINN) and Check-Cap (NASDAQ:MBAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

In the previous week, Check-Cap had 1 more articles in the media than Inspira Technologies OXY B.H.N.. MarketBeat recorded 1 mentions for Check-Cap and 0 mentions for Inspira Technologies OXY B.H.N.. Inspira Technologies OXY B.H.N.'s average media sentiment score of 0.00 equaled Check-Cap'saverage media sentiment score.

Company	Overall Sentiment
Inspira Technologies OXY B.H.N.	Neutral
Check-Cap	Neutral

Inspira Technologies OXY B.H.N. has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Check-Cap has lower revenue, but higher earnings than Inspira Technologies OXY B.H.N..

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspira Technologies OXY B.H.N.	$289K	97.02	-$13.22M	N/A	N/A
Check-Cap	N/A	N/A	$4.14M	-$14.07	N/A

12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 29.4% of Inspira Technologies OXY B.H.N. shares are held by insiders. Comparatively, 0.5% of Check-Cap shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A
Check-Cap	N/A	N/A	N/A

Summary

Inspira Technologies OXY B.H.N. beats Check-Cap on 4 of the 6 factors compared between the two stocks.

How does Check-Cap compare to Inspira Technologies OXY B.H.N.?

Check-Cap (NASDAQ:MBAI) and Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Check-Cap has higher earnings, but lower revenue than Inspira Technologies OXY B.H.N..

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$14.07	N/A
Inspira Technologies OXY B.H.N.	$290K	95.45	-$13.22M	N/A	N/A

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Check-Cap has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 4.24, indicating that its share price is 324% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A

In the previous week, Check-Cap and Check-Cap both had 1 articles in the media. Check-Cap's average media sentiment score of 0.00 equaled Inspira Technologies OXY B.H.N.'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inspira Technologies OXY B.H.N.	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Inspira Technologies OXY B.H.N. beats Check-Cap on 4 of the 5 factors compared between the two stocks.

How does Check-Cap compare to Accuray?

Accuray (NASDAQ:ARAY) and Check-Cap (NASDAQ:MBAI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

64.1% of Accuray shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 2.4% of Accuray shares are owned by company insiders. Comparatively, 0.5% of Check-Cap shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Check-Cap has lower revenue, but higher earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$401.95M	0.07	-$49.19M	-$0.40	N/A
Check-Cap	N/A	N/A	$4.14M	-$14.07	N/A

Check-Cap has a net margin of 0.00% compared to Accuray's net margin of -12.24%. Check-Cap's return on equity of 0.00% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accuray	-12.24%	-97.85%	-10.82%
Check-Cap	N/A	N/A	N/A

In the previous week, Accuray and Accuray both had 1 articles in the media. Accuray's average media sentiment score of 0.00 equaled Check-Cap'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accuray	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Accuray presently has a consensus price target of $2.00, indicating a potential upside of 786.92%. Given Accuray's stronger consensus rating and higher possible upside, research analysts plainly believe Accuray is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Accuray has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Summary

Accuray beats Check-Cap on 7 of the 12 factors compared between the two stocks.

How does Check-Cap compare to PetVivo?

PetVivo (NASDAQ:PETV) and Check-Cap (NASDAQ:MBAI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

In the previous week, PetVivo had 2 more articles in the media than Check-Cap. MarketBeat recorded 3 mentions for PetVivo and 1 mentions for Check-Cap. PetVivo's average media sentiment score of 0.00 equaled Check-Cap'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

24.5% of PetVivo shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 10.8% of PetVivo shares are owned by company insiders. Comparatively, 0.5% of Check-Cap shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PetVivo has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Check-Cap has lower revenue, but higher earnings than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	30.50	-$10.95M	-$0.34	N/A
Check-Cap	N/A	N/A	$4.14M	-$14.07	N/A

Check-Cap has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. Check-Cap's return on equity of 0.00% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
Check-Cap	N/A	N/A	N/A

Summary

PetVivo and Check-Cap tied by winning 6 of the 12 factors compared between the two stocks.

Get Check-Cap News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBAI vs. The Competition

Export

Metric	Check-Cap	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.78M	$5.58B	$7.31B	$13.29B
Dividend Yield	N/A	1.79%	2.52%	12.57%
P/E Ratio	-0.39	25.27	274.09	25.69
Price / Sales	N/A	71.58	642.55	79.71
Price / Cash	1.61	33.02	77.80	52.76
Price / Book	1.66	5.78	10.47	6.32
Net Income	$4.14M	$151.55M	$3.49B	$359.73M
7 Day Performance	-13.72%	0.01%	-0.68%	0.17%
1 Month Performance	-31.97%	-3.51%	-3.18%	-3.27%
1 Year Performance	N/A	6.37%	15.12%	5.58%

Check-Cap Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBAI Check-Cap	0.1889 of 5 stars	$5.47 -14.3%	N/A	N/A	$8.78M	N/A	N/A	85
PAVM PAVmed	2.3495 of 5 stars	$3.92 flat	$56.00 +1,328.6%	-69.3%	$31.36M	$70K	N/A	90	Gap Down
IINN Inspira Technologies OXY B.H.N.	N/A	$0.85 -1.1%	N/A	-39.1%	$30.40M	$289K	N/A	20	High Trading Volume
QTEX Inspira Technologies OXY B.H.N.	0.1398 of 5 stars	$0.83 -2.0%	N/A	N/A	$29.79M	$290K	N/A	20	News Coverage Gap Up
ARAY Accuray	1.7409 of 5 stars	$0.23 +1.1%	$2.00 +758.4%	-86.9%	$27.83M	$401.95M	N/A	1,040	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBAI) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Check-Cap (MBAI) Competitors